Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

LXR 623

Known as: LXR-623, LXR623 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
The LXR-623-induced long non-coding RNA LINC01125 suppresses the proliferation of breast cancer cells via PTEN/AKT/p53 signaling pathway
LXR-623 (WAY-252623), a liver X receptor agonist, reduces atherosclerotic plaque progression and remarkably inhibits the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2019
2019
Targeting the transcription factor receptor LXR to treat clear cell renal cell carcinoma: agonist or inverse agonist?
Growing evidence indicates that clear cell renal cell carcinoma (ccRCC) is a metabolism-related disease. Changes in fatty acid… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2019
2019
Activation of LXR Receptors and Inhibition of TRAP1 Causes Synthetic Lethality in Solid Tumors
Cholesterol is a pivotal factor for cancer cells to entertain their relentless growth. In this case, we provide a novel strategy… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2019
2019
SIRT2 plays a novel role on progesterone, estradiol and testosterone synthesis via PPARs/LXRα pathways in bovine ovarian granular cells
SIRT2 has been shown to possess NAD+-dependent deacetylase and desuccinylase enzymatic activities, it also regulates metabolism… Expand
Is this relevant?
Highly Cited
2016
Highly Cited
2016
An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers.
Small-molecule inhibitors targeting growth factor receptors have failed to show efficacy for brain cancers, potentially due to… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2015
Review
2015
Emerging small molecule drugs.
Dyslipidaemia is a major risk factor for cardiovascular diseases. Pharmacological lowering of LDL-C levels using statins reduces… Expand
Is this relevant?
2012
2012
Synergistic effect of liver X receptor activation and simvastatin on plaque regression and stabilization: an magnetic resonance imaging study in a model of advanced atherosclerosis.
AIMS The aim of this study was to investigate the effects of liver X receptors (LXRs)-β preferential activation by LXR-623 (WAY… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants.
Liver X-receptor (LXR) agonists have been postulated to enhance reverse cholesterol transport (RCT), a process believed to… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • table I
Is this relevant?
Highly Cited
2009
Highly Cited
2009
LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse[S]
Liver X receptors (LXRs) are ligand-activated transcription factors that coordinate regulation of gene expression involved in… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
2008
2008
Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells
BackgroundLXRs (Liver X Receptor α and β) are nuclear receptors that act as ligand-activated transcription factors. LXR… Expand
  • table 1
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE